KRAS and colorectal carcinoma: Results supported a prognostic relationship between increased DoR and longer survival post progression (PPS) in 841 patients with KRAS wild-type metastatic CRC treated with oxaliplatin or irinotecan-based chemotherapy regimens with or without cetuximab ( p < 0.0001 for CRYSTAL and p < 0.005 for OPUS).